Answers are grounded in this paper and cite their sources.
B-cell activating factor (BAFF) is a key regulator of B-cell homeostasis and is implicated in autoimmune and malignant B-cell disorders, yet its role in autophagy regulation during B-cell expansion remains unclear. Here, we examined whether human soluble BAFF (hsBAFF) promotes B-cell proliferation and viability through an AMPK-dependent FOXO3a–ATG5/Beclin 1 (BECN1) pathway. In Raji cells, Daudi cells, and primary murine B cells, hsBAFF dose-dependently increased phosphorylation of FOXO3a at Ser253 and BECN1 at Ser295, upregulated Bcl-2 and Survivin, and reduced ATG5 and LC3-II expression. These changes were accompanied by fewer MDC-labeled acidic vacuoles and GFP-LC3 puncta, together with increased B-cell proliferation and viability. ATG5 overexpression or expression of phosphorylation-deficient BECN1(S295A) attenuated hsBAFF-induced autophagy suppression and growth promotion, whereas ATG5 or BECN1 knockdown, BECN1(S295D), or FOXO3a knockout potentiated these effects. Mechanistically, hsBAFF inhibited AMPK activity; pharmacological or genetic AMPK activation restored FOXO3a-dependent autophagy and restrained B-cell proliferation/viability, whereas AMPK inhibition intensified hsBAFF responses. These findings identify AMPK-dependent FOXO3a–ATG5/BECN1 signaling as an autophagic checkpoint controlling BAFF-driven B-cell expansion and survival.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: